If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
88.00    1.90 (2.21%)
Bid:
88.90
Ask:
90.00
Spread: 1.10 (1.237%)
Market Cap: £144.27m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Disposal

11 Feb 2008 07:01

Yule Catto & Co PLC11 February 2008 Yule Catto & Co. plc Sale of James Robinson Yule Catto is an international producer of speciality chemicals, supplied toglobal customers for use in a wide range of industries includingpharmaceuticals, FMCG, paints and adhesives Yule Catto & Co plc ("Yule Catto" or the "Company") is pleased to announce thatit has exchanged conditional contracts with Vivimed Labs Limited ("Vivimed") forthe sale of the entire issued share capital of James Robinson Limited and otherassociated assets (together "James Robinson") for a consideration of $21.15million plus working capital of approximately $4.5 million. The considerationwill be paid as to $17.15 million plus the working capital amount in cash atcompletion and a further $4 million into escrow pending successful completion ofcertain product transfer arrangements. The completion of the sale is conditional on, amongst other things, Vivimedobtaining shareholder approval for the acquisition which is expected to beobtained by mid April 2008. The proceeds of the sale received by Yule Catto will be used to reduce theCompany's borrowings, and the transaction will be earnings accretive James Robinson carries on the development, manufacture and supply ofphotographic and photochromic chemicals and hair and other dyes. In the twelvemonths to 31 December 2006 it had sales of £17.8 million, an operating profit of£0.82 million and gross assets of £3.0 million. The James Robinson management team led by Dr Richard Smith will continue to runthe business. In addition, Yule Catto anticipates disposing of its interest in James RobinsonIndia (Private) Limited to its joint venture partner following the completion ofthe sale of James Robinson for a consideration of some $1.5 million. Adrian Whitfield, Chief Executive commented: "This sale is in line with YuleCatto's corporate strategy of delivering improved shareholder value from itsImpact Chemicals activities". 11 February 2008 ENQUIRIES: YULE CATTO Tel: 01279 442791Adrian Whitfield, Chief ExecutiveDavid Blackwood, Finance Director COLLEGE HILL Tel: 020 7457 2020Gareth DavidAnthony Parker This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Dec 20057:01 amRNSAdmission to trading on AIM
6th Dec 20054:23 pmRNSDirector Declaration
6th Dec 20054:18 pmRNSDirectorate Change
2nd Dec 200510:07 amRNSSale of Autoclenz Limited
15th Nov 20054:54 pmRNSHolding(s) in Company
31st Oct 20059:45 amRNSProposed sale - Autoclenz Ltd
5th Oct 20052:36 pmRNSDirector/PDMR Shareholding
29th Sep 200512:08 pmRNSDirector/PDMR Shareholding
14th Sep 20053:02 pmRNSHolding(s) in Company
17th Aug 20059:50 amRNSNotice of Results
13th Jul 20053:46 pmRNSChief Operating Officer
1st Jul 200511:15 amRNSJames Robinson Consolidation
10th Jun 20053:12 pmRNSDirector Shareholding
10th Jun 20053:09 pmRNSDirector Shareholding
3rd Jun 20053:16 pmRNSHolding(s) in Company
3rd Jun 20053:12 pmRNSHolding(s) in Company
3rd Jun 20053:11 pmRNSHolding(s) in Company
2nd Jun 200512:41 pmRNSBlocklisting Interim Review
2nd Jun 200511:21 amRNSHolding(s) in Company
1st Jun 20054:55 pmRNSHolding(s) in Company
26th May 20054:49 pmRNSDoc re. AGM Resolutions
26th May 200512:00 pmRNSAGM Statement
23rd May 200511:41 amRNSHolding(s) in Company
21st Apr 200510:36 amRNSAnnual Report and Accounts
31st Mar 20053:41 pmRNSSale of Brencliffe Limited
23rd Mar 20053:45 pmRNSDirector Shareholding
23rd Mar 20053:44 pmRNSDirector Shareholding
4th Mar 20054:16 pmRNSDirector Shareholding
3rd Mar 20057:00 amRNSFinal Results
15th Feb 20058:51 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.